Arun Kumar, Founder and Executive Chairperson of the Company, has served in various positions on the Board of Strides since its inception. His current appointment as Executive Director is expiring on ...

Strides Pharma Science is well on track to achieve the FY25 outlook of $275 million-$290 million, post-demerger.

Strides Pharma Science Ltd (BOM:532531) reports a robust quarter with 13.3% revenue growth and significant debt reduction, while navigating challenges in regulated markets.

Revenue increased 15% YoY at ₹1,153.7 crore from ₹1,005.8 crore in Q3 FY24, marking a consistent business growth.

Strides Pharma Science in its consolidated financial results for the quarter Q3FY25 ended December 31, 2024 reported revenues of Rs. 1,153.7 crore with a growth 14.6% YoY in Q3FY25. The PAT stood at ...

With the introduction of 200 daycare cancer centers, advanced diagnostics, improved access to treatment, and a ...

The theme this year for World Cancer Day, observed on February 4, 'United by Unique' is both, intriguing and relevant, as it ...

Bangalore: Strides Pharma Science Limited has announced that the Company has received an ESG score of 76/100 and CSA score of ...

With this achievement, Strides has secured a position in the ... the Company attained a commendable 87th percentile. Mr. Arun Kumar, Founder & Executive Chairperson, and Mr. Badree Komandur ...

Varun's journey is an example of a leader with strategic planning, and hard work who transformed a legacy into a global ...

Varanasi: Banaras Hindu University (BHU) celebrated its 110th foundation day with vibrant spring colours on the occasion of ...